Altimmune (NASDAQ:ALT) shares rise following alcohol-use disorder trial, with attention turning to $225 million in warrants
Altimmune stock gained roughly 10% in premarket trading on Tuesday. The company’s Phase 2 RECLAIM study showed pemvidutide achieved its primary endpoint. U.S. markets had not opened at the time of reporting.